Drugs / Enclitide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05261126 | Mar → Nov 2022 | familial hypercholesterolemia | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enclitide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05261126 ↗ |
| Known as | Enclitide Chloride | “Enclitide Chloride administered orally” NCT05261126 ↗ |
| Route | Oral | “Enclitide Chloride administered orally” NCT05261126 ↗ |